The molecular target of the disease must be precisely characterised in order to rationally build perfect precision therapeutics. This essay explores ways to address this need by modifying the current pharmaceutical development process. The next phase, the creation of precision drugs—medications that target illnesses with no, or very few, side effects—is demonstrated in the article using examples from earlier drug development. To do this, different molecular structures connected to illnesses must be found, and then drugs that particularly bind to these structures must be developed. Finally, future medication development must follow this new paradigm.
Karel Petrak,
Nangio Tx Inc., 50 Rector St Suite 1403 Newark, NJ07102, United States.
Please see the link here: https://stm.bookpi.org/CAPR-V4/article/view/7525
No comments:
Post a Comment